Hunter C Smith sold $709k of RYTM
Chief Financial Officer at RHYTHM PHARMACEUTICALS, INC.. 7,071 shares at an average of $100.21, traded Feb 10, 2026, filed Feb 12, 2026.
Score components
- +22RoleCFO
- +21Trade size$709k at market
- 0Share of holdings soldSold 5.6% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-014546, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | SOpen-market sale Common Stock10b5-1 | -1,913 | $102.66 | $196k | 123,624 | Feb 12, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock10b5-1 | -700 | $103.68 | $73k | 122,924 | Feb 12, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $104.76 | $10k | 122,824 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stock10b5-1 | -2,266 | $98.37 | $223k | 120,558 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $99.44 | $40k | 120,158 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $100.85 | $10k | 120,058 | Feb 12, 2026 |
| Feb 12, 2026 | SOpen-market sale Common Stock10b5-1 | -292 | $96.26 | $28k | 119,766 | Feb 12, 2026 |
| Feb 12, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $97.67 | $39k | 119,366 | Feb 12, 2026 |
| Feb 12, 2026 | SOpen-market sale Common Stock10b5-1 | -800 | $98.99 | $79k | 118,566 | Feb 12, 2026 |
| Feb 12, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $100.10 | $10k | 118,466 | Feb 12, 2026 |
| Feb 11, 2026 | AGrant or award Restricted Stock Unitsderivative10b5-1 | +25,000 | $0.00 | $0 | 25,000 | Feb 12, 2026 |
| Feb 11, 2026 | AGrant or award Stock Options (Right to Buy)derivative10b5-1 | +37,500 | $0.00 | $0 | 37,500 | Feb 12, 2026 |
Related signals
Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | RHYTHM PHARMACEUTICALS, INC. | David P Meeker President and CEO | $5.1M 50,000 shares | -17% | |
| 30Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $6.6M 62,774 shares | -36% | |
| 38Weak | RYTMsell RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $503k 5,614 shares | -97% | |
| 24Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $806k 7,954 shares | -7% | |
| 23Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $703k 6,628 shares | -5% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $372k 3,350 shares | -14% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $352k 3,350 shares | -14% | |
| 33Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $2.3M 22,866 shares | -57% | |
| 33Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $1.1M 9,748 shares | -53% | |
| 7Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $324k 2,815 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.